Implantable Cardioverter Defibrillators Show No Mortality Benefit in Certain Heart Attack Patients
New research at ESC 2025 suggests that implantable cardioverter defibrillators may not reduce mortality in certain post-heart attack patients with moderate LV dysfunction and arrhythmia risk markers.
Recent research presented at ESC Congress 2025 has questioned the effectiveness of implantable cardioverter defibrillators (ICDs) in reducing mortality among specific heart attack survivors. The study focused on patients with a history of myocardial infarction (MI), who also exhibited persistent moderate left ventricular (LV) systolic dysfunction and abnormal ECG markers indicative of increased arrhythmia risk.
The large, international REFINE-ICD trial involved nearly 2,000 post-MI patients across North America, Europe, the Middle East, and Africa. Participants underwent ambulatory ECG testing, assessing indicators like heart rate turbulence and T wave alternans, which are known to predict ventricular arrhythmias. Out of these, 597 patients with LVEF between 36-50%, impaired heart rate turbulence, and abnormal T wave alternans were randomized to receive a defibrillator along with optimal medical therapy or medical therapy alone.
The median age was 65 years, with 19% women. Overall, patients with both abnormal markers faced a higher risk of death. However, over an average follow-up of about 5.7 years, the study found no significant reduction in mortality due to ICD implantation. Deaths occurred at similar rates in both groups—24.5% in those with ICDs and 21.3% in the control group. Notably, nearly half of all deaths were non-cardiac, highlighting other factors influencing prognosis. Cardiac deaths and sudden cardiac death rates did not differ significantly between groups, indicating that the ICD did not provide a survival advantage for this patient subset.
Professor Derek Exner, lead investigator, summarized the findings, emphasizing that patients with prior MI, moderate LV dysfunction, and arrhythmia risk markers had a doubled risk of death compared to those without these risks. Yet, despite the higher risk profile, ICD therapy did not lead to a reduction in mortality or sudden cardiac death, suggesting a need to rethink intervention strategies for these patients. Further research is crucial to identify more effective methods for improving long-term outcomes in this high-risk group.
This study adds valuable insight into the ongoing evaluation of ICD utility beyond traditional indications and underscores the importance of personalized approaches to post-MI treatment.
Source: https://medicalxpress.com/news/2025-09-implantable-cardioverter-defibrillators-mortality-heart.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Parent-Driven Strategies Show Promise in Improving Communication for Deaf Toddlers
A new study reveals that parent-mediated interventions significantly improve communication skills in young children who are deaf or hard of hearing, especially when integrated with sign language education.
Targeting the Cerebellum to Alleviate Alcohol Withdrawal Symptoms: New Research Findings
New research from Washington State University suggests that targeting the cerebellum, a brain region traditionally associated with movement, could significantly reduce symptoms of alcohol withdrawal, paving the way for targeted therapies for alcohol use disorder.
Advancements in Digital Modeling: Creating Virtual Cell Laboratories for Future Research
Researchers have developed a new computer program that mimics cellular behavior across the body, paving the way for virtual cell laboratories to test drugs and study biological processes more efficiently.
Reinstatement of Hundreds of Laid-Off CDC Employees Marks a Shift in Public Health Workforce
Over 460 CDC employees who were laid off earlier this year are now being reinstated, signaling a shift in federal public health staffing. Learn more about the ongoing impact on CDC programs and operations.